In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma

References

• Cancer incidence in five continents. Volume VII Iarc SCI Publ1997ixxxiv11240
   Google Scholar
• WeiKRZhengRSZhangSWLiangZHOuZXChenWQNasopharyngeal carcinoma incidence and mortality in China in 2010Chin J Cancer201433838138725096544
   PubMedGoogle Scholar
• ZhangLFLiYHXieSHIncidence trend of nasopharyngeal carcinoma from 1987 to 2011 in Sihui County, Guangdong Province, South China: an age-period-cohort analysisChin J Cancer201534835035726058679
   PubMedGoogle Scholar
• MaBBHuiEPChanATSystemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directionsCancer Sci20089971311131818498420
   PubMed Web of Science ®Google Scholar
• XiaoWWHuangSMHanFLocal control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 studyCancer201111791874188321509764
   PubMed Web of Science ®Google Scholar
• NganRKYiuHHLauWHCombination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II studyAnn Oncol20021381252125812181249
   PubMed Web of Science ®Google Scholar
• TanEHKhooKSWeeJPhase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinomaAnn Oncol199910223523710093695
   PubMed Web of Science ®Google Scholar
• ZhangLZhangYHuangPYXuFPengPJGuanZZPhase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapyCancer Chemother Pharmacol2008611333817909810
   PubMed Web of Science ®Google Scholar
• MaBBHuiEPWongSCMulticenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma – correlation with excision repair cross-complementing-1 polymorphismsAnn Oncol200920111854185919549713
   PubMed Web of Science ®Google Scholar
• WangCCChangJYLiuTWLinCYYuYCHongRLPhase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinomaHead Neck2006281748016331692
   PubMed Web of Science ®Google Scholar
• FujiiMYamashitaTIshiguroRTashiroMKameyamaKSignificance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinomaAuris Nasus Larynx200229217518111893453
   PubMed Web of Science ®Google Scholar
• MaBBPoonTCToKFPrognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopha-ryngeal carcinoma – a prospective studyHead Neck2003251086487212966511
   PubMed Web of Science ®Google Scholar
• SheenTSHuangYTChangYLEpstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinomaJpn J Cancer Res199990121285129210665644
   PubMedGoogle Scholar
• ChuaDTNichollsJMShamJSAuGKPrognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapyInt J Radiat Oncol Biol Phys2004591112015093894
   PubMed Web of Science ®Google Scholar
• LeeSCLimSGSooRLack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinomaPharmacogenet Genomics2006161737416344724
   PubMed Web of Science ®Google Scholar
• ChuaDTWeiWIWongMPShamJSNichollsJAuGKPhase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinomaHead Neck200830786386718213730
   PubMed Web of Science ®Google Scholar
• MaBHuiEPKingAA phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacyCancer Chemother Pharmacol2008621596417762933
   PubMed Web of Science ®Google Scholar
• LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
   PubMed Web of Science ®Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
   PubMed Web of Science ®Google Scholar
• SchutzeCDorflerAEichelerWCombination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinomaStrahlenther Onkol2007183525626417497097
   PubMed Web of Science ®Google Scholar
• KhelwattySAEssapenSSeddonAMModjtahediHGrowth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family membersInt J Oncol201139248349121617858
   PubMed Web of Science ®Google Scholar
• IoannouNDalgleishAGSeddonAMAnti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cellsBr J Cancer2011105101554156221970876
   PubMed Web of Science ®Google Scholar
• YoungNRSoneruCLiuJAfatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivoTarget Oncol201510450150825559287
   PubMed Web of Science ®Google Scholar
• SeiwertTYFayetteJCupissolDA randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckAnn Oncol20142591813182024928832
   PubMed Web of Science ®Google Scholar
• MachielsJPHaddadRIFayetteJAfatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialLancet Oncol201516558359425892145
   PubMed Web of Science ®Google Scholar
• XueCHuangYHuangPYPhase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinomaAnn Oncol20132441055106123172635
   PubMed Web of Science ®Google Scholar
• ChouTCDrug combination studies and their synergy quantification using the Chou-Talalay methodCancer Res201070244044620068163
   PubMed Web of Science ®Google Scholar
• HuiEPLuiVWWongCSPreclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinomaInvest New Drugs20112961123113120467883
   PubMed Web of Science ®Google Scholar
• LiTLingYHGoldmanIDPerez-SolerRSchedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cellsClin Cancer Res200713113413342217545550
   PubMed Web of Science ®Google Scholar
• WuYLLeeJSThongprasertSIntercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trialLancet Oncol201314877778623782814
   PubMed Web of Science ®Google Scholar
• SantosCDTijeras-RaballandASerovaMEffects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinomaBr J Cancer20151121869425422908
   PubMed Web of Science ®Google Scholar